Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice

Effect of perductal paclitaxel exposure on the development of MNU-induced mammary carcinoma in female S–D rats

“…Further, paclitaxel via ip injection showed antitumor activity in breast cancer xenografts in nude mice, and there were no differences between ip and iv administration [11,12]. However, it remains unclear whether the intraductal approach of paclitaxel is effective to mammary carcinoma, although breast carcinoma and precancer are thought to start in the lining of the milkduct or lobule.…”

“…MNU solution was freshly prepared, dissolved in physiologic saline containing 0.05% acetic acid, just before use. Paclitaxel was kindly provided from Bristol-Myers KK (Tokyo) and dissolved at 30 mg/ml in ethanol/Cremophor EL Ò solution, and stored at 4°C [19]. This stock solution was further diluted to 2 mg/ml with 0.9% NaCl on the day of administration, and paclitaxel in 0.1 ml of this solution was injected.…”

UCN‐01 (7‐Hydoxystaurosporine) Inhibits in vivo Growth of Human Cancer Cells through Selective Perturbation of G1 Phase Checkpoint Machinery

“…In this study, we assessed the antitumor activity of UCN-01 on three human tumor xenografts serially trans-planted into nude mice. While two pancreatic cancer xenografts insensitive to conventional agents 37,38) were sensitive to UCN-01, the MX-1 xenograft, sensitive to conventional agents, 40,41) was resistant to UCN-01. This indicated that UCN-01 has a different antitumor spectrum compared to other agents.…”

“…MX-1 is defined histologically as an invasive ductal carcinoma and is sensitive to conventional antitumor agents. 40,41) All xenografts were maintained in our laboratory as serially transplantable tumors in nude mice. Tumor inoculation, measurement of tumor size, and evaluation of agent activity Male nude mice with a BALB/c genetic background (CLEA Japan Co., Ltd., Tokyo) were maintained under specific pathogen-free conditions using an Isorack in our experimental animal center.…”